208 related articles for article (PubMed ID: 25642941)
1. The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model.
Matthijsse SM; van Rosmalen J; Hontelez JA; Bakker R; de Kok IM; van Ballegooijen M; de Vlas SJ
PLoS One; 2015; 10(2):e0116618. PubMed ID: 25642941
[TBL] [Abstract][Full Text] [Related]
2. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
3. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
4. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus.
Bogaards JA; Xiridou M; Coupé VM; Meijer CJ; Wallinga J; Berkhof J
Am J Epidemiol; 2010 Apr; 171(7):817-25. PubMed ID: 20231211
[TBL] [Abstract][Full Text] [Related]
5. Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.
Beachler DC; Jenkins G; Safaeian M; Kreimer AR; Wentzensen N
J Infect Dis; 2016 May; 213(9):1444-54. PubMed ID: 26690341
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
7. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
[TBL] [Abstract][Full Text] [Related]
8. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.
Simen-Kapeu A; Kataja V; Yliskoski M; Syrjänen K; Dillner J; Koskela P; Paavonen J; Lehtinen M
Scand J Infect Dis; 2008; 40(9):745-51. PubMed ID: 19086247
[TBL] [Abstract][Full Text] [Related]
9. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
10. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of HPV-mediated immune alterations in cervical cancer.
Chen L; Luan S; Xia B; Liu Y; Gao Y; Yu H; Mu Q; Zhang P; Zhang W; Zhang S; Wei G; Yang M; Li K
Gynecol Oncol; 2018 May; 149(2):248-255. PubMed ID: 29572030
[TBL] [Abstract][Full Text] [Related]
12. The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer.
Malik T; Reimer J; Gumel A; Elbasha EH; Mahmud S
Math Biosci Eng; 2013 Aug; 10(4):1173-205. PubMed ID: 23906207
[TBL] [Abstract][Full Text] [Related]
13. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.
Kim S; Arduino JM; Roberts CC; Marsico M; Liaw KL; Skjeldestad FE
Sex Transm Dis; 2011 Jul; 38(7):587-97. PubMed ID: 21301390
[TBL] [Abstract][Full Text] [Related]
14. More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population.
Marais DJ; Sampson C; Jeftha A; Dhaya D; Passmore JA; Denny L; Rybicki EP; Van Der Walt E; Stephen LX; Williamson AL
BMC Infect Dis; 2006 Jun; 6():95. PubMed ID: 16762074
[TBL] [Abstract][Full Text] [Related]
15. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
16. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
18. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
Delvenne P
Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
[TBL] [Abstract][Full Text] [Related]
19. Estimated impact of human papillomavirus vaccines on infection burden: The effect of structural assumptions.
van Schalkwyk C; Moodley J; Welte A; Johnson LF
Vaccine; 2019 Aug; 37(36):5460-5465. PubMed ID: 31331772
[TBL] [Abstract][Full Text] [Related]
20. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
Kohl I
Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
